With CaaS, companies benefit from:
• Faster market entry through ready-made networks
• End-to-end support, from regulatory approvals to post-launch
• Reduced risk and complexity, with a single accountable partner
Setting a New Industry Standard
KEMEDICA’s CaaS model is already transforming market entry strategies for European pharma innovators expanding into the Middle East and beyond.
By owning the END-TO-END connection process, KEMEDICA enables partners to focus on what matters most: bringing advanced therapies to patients more quickly and efficiently.
“We founded KEMEDICA with a clear vision: to break down the barriers that prevent life-changing therapies from reaching the patients and regions that need them most. Commercialization as a Service (CaaS) is our answer, a unique, fully managed solution that orchestrates regulatory, commercial, and distribution networks as a turnkey service.”
Maikel Gobran, Managing Director of KEMEDICA GmbH.
TRADITIONAL MODEL
Multiple vendors. Diluted accountability
Unified regulatory strategy across 17+ markets
Curated, vetted distributor network
In-house marketing, medical, and access teams
European-standard governance & legal entity
Single regional P&L and performance dashboard
KEMEDICA CaaS MODEL
One partner. One contract. One regional plan.
Separate regulatory consultant per market
Independent distributor in each country
Local marketing agency engagements per market
The manufacturer carries the coordination cost
No single P&L view of the region
CaaS replaces the traditional, fragmented chain of consultants, regulatory agents, distributors, and country managers with a single, accountable, end-to-end commercial partner.
